

INTERIM FORMULARY UPDATE

The following recommendations, made at the October 12, 2007 meeting of the Executive Formulary Committee, are approved:

Dosage strength/formulations **recommended to be deleted** from to the DADS/DSHS Drug Formulary based on the Sectional Reviews for Dermatological Agents, Part 1 and the SSRI Review:

Generic Name	Brand Name	Dosage Form	Dosage forms still available
calcium undecylenate	Caldesene®	Powder, topical: 10%	None
zinc undecylenate	Desenex®	Cream, topical: 20% Foam, topical: 10% [with 35.2% alcohol] Ointment, topical: 30gm Powder, topical: 19%	None
paroxetine	Paxil®	Tablet, controlled release: 12.5 mg, 25 mg, 37.5 mg	Tablet: 10 mg, 20 mg, 30 mg, 40 mg

Feedback will be obtained from the field regarding the proposed deletions.

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
tamsulosin	Flomax®	Capsule, sustained release: 0.4 mg	Genitourinary; Miscellaneous
pregabalin	Lyrica®	Capsule: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, 300 mg	Anticonvulsant

Product(s) **denied addition** to the DADS/DSHS Drug Formulary based on New Drug Applications:

Generic Name	Brand Name	Dosage Form	Classification
None			

Product(s) **approved to be added** to the DADS/DSHS Drug Formulary based on the Sectional Reviews for Dermatological Agents, Part 1 and the SSRI Review:

Generic Name	Brand Name	Dosage Form	Classification
salicylic acid/sulfur		Bar : Shampoo:	Topical; Dermatologicals; Acne Agents, Skin cleanser, Antiseborrheic Agent
doxepin	Zonalon®	Cream: 5%	Topical, Dermatologicals; Anti-Histamine Agent
ciclopirox	Loprox®, Penlac®	Shampoo: 1% Solution, Topical: 8%	Topical, Dermatologicals; Anti-Infective; Antifungal

Dosage strength(s) **recommended to be added** to the DADS/DSHS Drug Formulary based on the Sectional Reviews for Dermatological Agents, Part 1 and the SSRI Review:

Generic Name	Brand Name	Dosage Form	Classification
escitalopram	Lexapro®	Solution: 5 mg/5 ml	Psychotropic Agents; Antidepressants
paroxetine	Paxil®	Suspension: 10 mg/5 ml	Psychotropic Agents; Antidepressants

Other recommendations:

- Change the clozapine (Clozaril® and Fazaclo®) Guidelines for Use to match the Clozapine Audit Criteria.
- Remove divalproex (Depakote®) ER from the reserve category.

Other **recommendation(s)/addition(s)/revisions(s)** to the DADS/DSHS Drug Formulary:

1. Add current formulary agents to additional section:
 - a. Acne Agents – Tazarotene (Tazorac®, Avage®), Sulfacetamide sodium (Sebizon®)
 - b. Diaper Rash Agents – Zinc oxide
 - c. Antiseborrheic Agents – Coal tar
 - d. Antipsoriatics – Coal tar
2. Add dosage forms of current formulary agents:
 - a. Non-soap cleanser: bar
 - b. Salicylic acid – Wash; Shampoo; Cleanser
3. Additional trade names to add to current formulary agents:
 - a. Abrasive Cleanser – Salac®
 - b. Salicylic acid - Salex®, Neutrogena®
4. Move Burn Agents section under Anti-Infective
5. Move Antiseptics & Germicides under Anti-Infective
6. Add Wound Healing Agents to Dermatological Section

Approved:



Pharmacy Services Director
San Antonio State Hospital